Omadacycline Tosylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Omadacycline Tosylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
28
Registered trials
29
Result records
6
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Omadacycline Tosylate can convert its Small molecule drug profile and 30S subunit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Omadacycline Tosylate (query alias: omadacycline) |
|---|---|
| Modality / target | Small molecule drug; 30S subunit; 30S subunit inhibitors |
| Highest global status | Approved |
| Originator | Paratek Pharmaceuticals, Inc. |
| Active developers | Paratek Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd., Zai Lab (Hong Kong) Ltd. |
The MCP disease footprint includes Community-acquired bacterial pneumonia, Skin and skin structure infections, Hospital acquired bacterial pneumonia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06162286 | Phase 3 | Unknown status | 100 | Overall assessment of clinical response rate at post therapy evaluation (PTE) timepoint in the mITT population. |
| NCT06462326 | Phase 1 | Completed | 24 | Changes in the types of microbial resistomes. |
| NCT07228702 | Phase 1 | Enrolling by invitation | 1 | Microbiologic: Response |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Pharmacokinetics of Omadacycline in Patients With Cystic Fibrosis
Phase 4; n=9; evaluation: not stated. Reported fields: -; -; Omadacycline IV(Mean) = 0.733 mg/L (Standard Deviation, 0.226)
A Phase 1, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Oral Doses of Omadacycline in Pediatric Subjects With Suspected or Confirmed Bacterial Infections
Phase 1; n=23; evaluation: not stated. Reported fields: -; -; Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 48hours (AUC0-48) of Omadacycline After IV Infusion(Geometric Mean) = 8990 hours*nanograms per milliliter (h*ng/ml) (Geometric Coefficient of Variation, 27.3)
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex
Phase 2; n=66; evaluation: not stated. Reported fields: Percentage of Participants With Clinical Response on NTM Symptom Assessment Scale at Day 84 = 20.0 Percentage of participants ; Percentage of Participants With Clinical Response on NTM Symptom Assessment Scale at Day 84: Difference in response rates = 14.15, P-Value = 0.2182; Percentage of Participants With Clinical Response on NTM Symptom Assessment Scale at Day 84 = 34.1 Percentage of participants
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Omadacycline Tosylate addresses Community-acquired bacterial pneumonia, Skin and skin structure infections, Hospital acquired bacterial pneumonia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-06-06 | Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals | Approved | US$462.0M stated total |
| 2020-03-20 | 瀚晖制药与再鼎医药达成战略合作，携手并肩探索全球领先抗感染药物 | Approved | Financial terms not disclosed |
| 2017-04-24 | Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China | Phase 3 | US$7.5M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Process for the preparation of omadacycline tosylate”. The milestone feed surfaced a patent-application signal described as “A freeze dried parenteral composition of omadacycline tosylate with improved stability”. The milestone feed surfaced a patent-application signal described as “Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
